Description
Tumor-infiltrating lymphocytes (TILs) are a form of adoptive cell therapy that utilizes a patient's own immune cells extracted from tumor tissue. The lymphocytes are expanded in the laboratory and then reinfused into the patient to enhance the immune system's ability to recognize and destroy cancer cells. This personalized immunotherapy approach harnesses the body's natural tumor-fighting T cells that have already demonstrated the ability to penetrate the tumor microenvironment.
Mechanism of Action
TILs work by expanding populations of T cells that have already shown tumor-specific recognition capabilities, then reintroducing them in large numbers to overwhelm cancer defenses. The therapy typically involves lymphodepletion prior to cell infusion, followed by IL-2 administration to support T cell survival and proliferation in vivo.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.